Literature DB >> 25342430

Antiangiogenic effect of itraconazole on corneal neovascularization: a pilot experimental investigation.

Sertan Goktas1, Rabia Sakarya, Ender Erdogan, Yasar Sakarya, Muammer Ozcimen, Duygu Dursunoglu, Metin Kocacan, Ismail Alpfidan, Erkan Erdogan, Abdulkadir Bukus, Ismail Senol Ivacık.   

Abstract

PURPOSE: To investigate the antiangiogenic effect of itraconazole for the prevention of experimentally induced corneal neovascularization and whether the efficacy depends on the route of administration.
MATERIALS AND METHODS: Thirty-six rats were randomly divided into 6 groups with 6 rats in each group. Chemical cauterization of the cornea was performed using silver nitrate/potassium nitrate sticks, and the rats were subsequently treated daily with topical (10 mg/ml), subconjunctival (10 mg/ml) or intraperitoneal (19 mg/kg) itraconazole for 7 days. Control rats received topical, subconjunctival or intraperitoneal 0.9% saline. On the 8th day of the experiment, the rat corneas were photographed to determine the percentage area of the cornea covered by neovascularization. The maximum density of corneal neovascularization was determined by microscopy.
RESULTS: The median percentage of corneal neovascularization for group 1 was 31.5% (95% confidence interval, 27.5-35.5%); in group 3, it was 32% (23.5-39.8%); in group 5, it was 47% (36.3-60.0%). The percentages of corneal neovascularization in groups 2, 4 and 6 (the control groups) were 70% (95% confidence interval, 60.7-77.3%), 69% (63.0-77.7%) and 68% (56.5-78.5%), respectively. The area of neovascularization was smaller after itraconazole treatment as compared to saline treatment. Further, the area of neovascularization was smaller after topical and subconjunctival administration than after intraperitoneal administration. Histological evaluation of the corneas showed the most extensive corneal neovascularization in the control group. No local or systemic adverse effects were seen from either treatment group.
CONCLUSION: Itraconazole reduces corneal neovascularization shortly after chemical burn. However, a larger experimental study is necessary to confirm the data of this investigation.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25342430     DOI: 10.1159/000366283

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  5 in total

1.  Effect of itraconazole on the cornea in a murine suture model and penetrating keratoplasty model.

Authors:  Yang Kyung Cho; Eun Young Shin; Hironori Uehara; Balamurali Ambati
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

Review 2.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

3.  Management of Head and Neck Hemangiomas in Adults: Oral Propranolol Versus Oral Itraconazole in Conjugation with Injection Sodium Tetra Decyl Sulphate.

Authors:  Siddharth Panditray; Sauvagini Acharya; Nilamadhab Prusty; Subha Saumya Dany
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-06-04

4.  Intravitreal itraconazole inhibits laser-induced choroidal neovascularization in rats.

Authors:  Jeong Hun Bae; Ah Reum Hwang; Chan Yun Kim; Hyeong Gon Yu; Hyoung Jun Koh; Woo Ick Yang; Hae Ran Chang; Sung Chul Lee
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

Review 5.  Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization.

Authors:  Zachary Barry; Bomina Park; Timothy W Corson
Journal:  Molecules       Date:  2020-07-30       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.